Better diagnostics for thrombosis are a matter of resources

Better diagnostics for thrombosis are a matter of resources

Cost-effectiveness is paramount for any new medical technology. If pharmaceutical companies do not see a profit, new drugs will never see the light of day. And if insurance companies think a new treatment is more expensive than the old one, they will simply not pay. Take thrombosis, or blood clotting, which affects millions of people worldwide. Blood thinners, like coumarins, are amongst the most widely used drugs to prevent blood clotting. But getting dosage right is a very challenging problem and errors have led to hospitalisations. The need for accurate dosage testing is thus clear. But they will have to be cost-effective to enter clinical practice.

The EU funded project, EU-PACT, completed in 2013 aimed to do just that. "We've looked at the possibility of using companion diagnostics alongside the treatment of thrombosis," says project coordinator Anke-Hilse Maitland-van der Zee, associate professor of personalised medicine at the University of Utrecht, in the Netherlands. "Thrombosis is treated with coumarins, , and getting the exact dosage right is difficult. Too much can have severe effects, like internal bleeding. Too little means blood clots can form, that's just as bad, or worse. But companion diagnostics—[that is] genotyping the patient in order to see what drug, and in what quantity, might be most beneficial—could help in this case," she tells youris.com.

The project developed a DNA that looked for two genetic variants. Those variants can predict the correct dosage of coumarin before therapy begins. Within the test cohort of 500 patients the right dosage was found in three weeks instead of four, and over a period of three months they remained at the correct dosage 67% of the time. With previous approaches, it was 60%. Not a huge difference, but an improvement nonetheless.

But uncertainty still remains about cost-effectiveness. " Coumarins are very cheap, the patent ran out decades ago," Maitland tells youris.com. "So the DNA test should also be very cheap in order to make a real difference. Even 80 euros per test could be too much. What's more, coumarins are rather old fashioned. These days there are new anti-coagulants - noacs- which are much quicker, and at least as effective as coumarins. So I'm afraid will not be interested in bringing our test to the market… We still need to do a proper cost-effectiveness analysis. Only then can we give a valid advice; should the test be standard or not."

But an independent expert is more optimistic. "Companion diagnostics have proven to be a real money saver in the development and therapeutic use of new anticancer drugs like Iressa and Herceptin. It stands to reason the same will be true of this new test to go with coumarin therapy," says Jan Tröst Jörgensen, director of the Dx-Rx Institute in Copenhagen, Denmark. "Herceptin for example only works against a very aggressive type of breast cancer that only women with a relatively rare genetic marker suffer from. Giving these women another drug is a waste of money. Giving patients too much or too little is just as wasteful," he tells youris.com.

Another expert is equally optimistic and believes in the DNA-test's commercial viability. "Noacs may be quicker. But after about a month into the therapy there is no difference with coumarins," says Colin Palmer, professor of pharmacogenomics and chair at the Ninewells Medical Research Institute, University of Dundee, Scotland. "And noacs are very expensive, so avoiding them and staying with the old and trustworthy coumarins might be financially worthwhile. That's where I believe the DNA-test developed by the project may come in handy."

add to favorites email to friend print save as pdf

Related Stories

Coumarins show potency as anti-inflammatory drugs

Nov 25, 2013

New methods for the laboratory-scale synthesis of coumarin-based drugs were developed in a recent study completed at the University of Eastern Finland. In his doctoral thesis, Lic. Phil. Juri Timonen also developed new analytical ...

Schizophrenia enters the molecular diagnostics era

Feb 12, 2014

With a drop of blood and some laboratory analyses, doctors have been able to tell patients whether they suffer from diabetes or some sort of cancer. Measuring changes in the cells or molecules of human tissues ...

Video: New blood test for schizophrenia

Feb 12, 2014

Currently the diagnosis of most mental illnesses is based on conversations and questionnaires. These could now be supported by a new low-cost blood test developed within the European research project SchizDX.

Recommended for you

The impact of bacteria in our guts

4 hours ago

The word metabolism gets tossed around a lot, but it means much more than whether you can go back to the buffet for seconds without worrying about your waistline. In fact, metabolism is the set of biochemical ...

Stem cell therapies hold promise, but obstacles remain

4 hours ago

(Medical Xpress)—In an article appearing online today in the journal Science, a group of researchers, including University of Rochester neurologist Steve Goldman, M.D., Ph.D., review the potential and ch ...

New hope in fight against muscular dystrophy

5 hours ago

Research at Stockholm's KTH Royal Institute of Technology offers hope to those who suffer from Duchenne muscular dystrophy, an incurable, debilitating disease that cuts young lives short.

Biologists reprogram skin cells to mimic rare disease

23 hours ago

Johns Hopkins stem cell biologists have found a way to reprogram a patient's skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. ...

User comments